(以下内容从信达证券《医药生物行业周报:艾伯维19.25亿美元引进CD3/BCMA/CD38三抗,关注TCE多抗的投资机遇》研报附件原文摘录)本期内容提要:上周市场表现:上周医药生物板块收益率为2.82%,板块相对沪深300收益率为+1.56%,在31个一级子行业指数中涨跌幅排名第6。6个子板块中,医疗服务板块周涨幅最大,涨幅7.73%(相对沪深300收益率为+6.48%);涨幅最小的为医药商业,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.